Clinical studies have revealed direct correlations between reduced serum FGF21 levels and the development of various CVDs, such as myocardial ischemia, CAD, cardiac hypertrophy, atherosclerosis, and diabetic cardiomyopathy, supporting the protective function of endogenous FGF21 against CVDs. Here, FGF21 is linked to cardiac hypertrophy.